Marinus Pharma (MRNS) Announces Elan Ezickson to Board

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) announced today that Elan Ezickson, has joined the Company’s Board of Directors. Mr. Ezickson is a highly accomplished executive with over 30 years of experience in the life sciences industry across commercial, operational and strategic leadership roles.

“We are thrilled to welcome Elan to our board of directors,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus. “His diverse leadership experience across the entire value chain of pharmaceutical operations, from capital raising to program development, will be invaluable to Marinus as we continue to execute on the clinical development of ganaxolone across multiple registrational Phase 3 studies. We look forward to leveraging his valuable insight as we prepare for significant regulatory and clinical milestones in 2020.”

Mr. Ezickson brings extensive biopharmaceutical operational, strategic and capital formation expertise to Marinus’s board, most recently having served as the Chief Operating Officer and head of corporate development at Scholar Rock Holding Corporation, a clinical stage biotechnology company focused on novel oncology and rare disease treatments. At Scholar Rock, Mr. Ezickson directed corporate development, operations and strategy, and played a significant role in corporate finance, leading the company’s initial public offering. Prior to joining Scholar Rock, Mr. Ezickson served as Executive Vice President and Chief Operating Officer of Aveo Pharmaceuticals where he built and oversaw corporate development, commercial operations, technical operations, medical affairs, program management and legal functions and led capital raising and licensing efforts with multinational pharmaceutical companies. Prior to Aveo, he was at Biogen in roles that included President of Biogen Canada, Program Executive and Associate General Counsel. Mr. Ezickson holds a Bachelor of Arts degree in political science from Yale University and a Juris Doctorate from the Columbia University School of Law.

Mr. Ezickson also currently serves on the Boards of Directors of three clinical stage biotechnology firms including Carmine Therapeutics, Tvardi Therapeutics and Ziopharm Oncology.

You May Also Be Interested In

• CopperTech Metals files for IPO on NYSE under ticker CUX
• Bending Spoons valuation up to $19 Billion in U.S. IPO - Reuters
• indie Semiconductor co-founder Aoki to retire, Schiller joins board